Malnutrition Clinical Trial
Official title:
A Multicenter, Prospective, Controlled, Longitudinal-Cohort Study Assessing the Safety of Omegaven in Pediatric Patients With Parenteral Nutrition-Associated Cholestasis (PNAC)
NCT number | NCT04807478 |
Other study ID # | OMEG-038-CP4 |
Secondary ID | |
Status | Withdrawn |
Phase | |
First received | |
Last updated | |
Start date | April 1, 2022 |
Est. completion date | May 1, 2029 |
Verified date | August 2022 |
Source | Fresenius Kabi |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
This study will demonstrate Short-, mid-, and long-term safety in pediatric patients with Parenteral Nutrition-Associated Cholestasis treated with Omegaven®, which is indicated as a source of calories and fatty acids in this patient population
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | May 1, 2029 |
Est. primary completion date | May 1, 2028 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 1 Day and older |
Eligibility | Inclusion Criteria: 1. Patient's parent(s) or legal guardian(s) has provided a signed and dated Informed Consent Form (ICF). 2. Patient is PN-dependent and within the past 21 days has been diagnosed with PNAC, defined as direct or conjugated bilirubin (DBil) = 2.0 mg/dL with no other known cause of liver dysfunction at the time of enrollment. 3. Patient has feeding intolerance or at least one gastrointestinal disorder requiring PN. 4. Patient is < 6 months corrected age (expected time of delivery to time of screening). Exclusion Criteria: 1. Patient has any other known cause of chronic liver disease such as hepatitis C, cystic fibrosis, biliary atresia, alpha-1-antitrypsin deficiency, passive hepatic congestion due to heart failure, etc. 2. Patient has known cirrhosis (liver biopsy is not required under this protocol). 3. Patient has known portal vein thrombosis (imaging studies are not required under this protocol). 4. Patient has previously received a liver-only or liver-inclusive transplant. 5. Patient has a major cardiac anomaly with hemodynamic instability. 6. Patient has a major life-threatening disease (e.g., sepsis requiring high-dose vasopressors, acute respiratory distress syndrome, veno-occlusive disease, cancer). 7. Patient has multi-organ failure, septic shock, hypotension requiring pressor therapy, persistent pulmonary hypertension requiring inhaled nitric oxides, or requires extracorporeal membrane oxygenation (ECMO) or similar intervention. 8. Patient has renal failure and requires dialysis. 9. Patient has a severe hemorrhagic disorder. 10. Patient has an INR > 2.0. 11. Patient has severe hyperlipidemia or a severe disorder of lipid metabolism characterized by hypertriglyceridemia (i.e., serum triglyceride level > 1,000 mg/dL). 12. Patient has a record of a previous T:T ratio = 0.2 or had a previous diagnosis of EFAD. 13. Patient has a central nervous system anomaly (e.g., anencephaly) or any injury (e.g., grade 3 or 4 intraventricular hemorrhage, moderate to severe hypoxic ischemic encephalopathy) that will affect neurodevelopment. 14. Patient has been diagnosed with or is suspected to have a genetic disorder known to be associated with neurodevelopmental impairment (e.g., trisomy 21, 18, 13). 15. Patient has been diagnosed with or is suspected to have an inborn error of metabolism. 16. Patient has a known hypersensitivity to fish or egg protein or to any of the active ingredients or excipients of Omegaven. 17. Patient's medical care has been deemed futile by the medical team. 18. Patient is enrolled in any other study with an investigational medicinal product. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Fresenius Kabi |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Adverse events (AEs)/serious adverse events (SAEs) | The incidence of adverse events (AEs)/serious adverse events (SAEs) | Through study completion, a maximum of 6 years | |
Primary | Incidence of: | Incidence of EFAD
Incidence of serious bleeding events Incidence of life-threatening pericardial effusion events Incidence of life-threatening pleural effusion events Severity of any neurodevelopmental delays. |
Through study completion, a maximum of 6 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04448041 -
CRANE Feasibility Study: Nutritional Intervention for Patients Undergoing Cancer Surgery in Low- and Middle-Income Countries
|
||
Completed |
NCT03268902 -
Early Life Interventions for Childhood Growth and Development In Tanzania
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT04746664 -
Effects of Nutrition Counselling on Old Age People's Nutritional Status and Quality of Life in Bahir Dar City, North West Ethiopia
|
N/A | |
Completed |
NCT04608656 -
Livestock for Health Project
|
N/A | |
Completed |
NCT06009198 -
Nutritional, and WASH Related Education Intervention to Address Malnutrition of Early Adolescents in Pakistan
|
N/A | |
Recruiting |
NCT05417672 -
Assessment of Relationship Between Preoperative Nutritional Status and Perioperative/Postoperative Conditions in Patients With Lung Cancer Scheduled for Lobectomy
|
||
Recruiting |
NCT05257980 -
Evaluation of Four New Ready to Drink Oral Nutritional Supplements: Adult ONS Trial
|
N/A | |
Completed |
NCT03628196 -
A Nutrition-Focused QIP in Outpatient Clinics
|
||
Completed |
NCT05015647 -
Low Protein Diet in CKD Patients at Risk of Malnutrition
|
N/A | |
Enrolling by invitation |
NCT04675229 -
Extending the Validation of SCREEN to Persons Living With Dementia or in Retirement Homes
|
||
Recruiting |
NCT04627376 -
Multimodal Program for Cancer Related Cachexia Prevention
|
N/A | |
Not yet recruiting |
NCT05860556 -
Sustainable Eating Pattern to Limit Malnutrition in Older Adults
|
||
Not yet recruiting |
NCT06047054 -
Incidence Rate and Risk Factors of Malnutrition in ICU
|
||
Not yet recruiting |
NCT04398836 -
Preoperative Nutrition for Crohn's Disease Patients
|
Phase 3 | |
Not yet recruiting |
NCT04183075 -
Impact of a Nutritional Supplement on the Recovery of the Nutritional Status of Patients With Spontaneous Hip Fracture
|
N/A | |
Not yet recruiting |
NCT03150927 -
Clinical Study of Novel Probiotic Microbial Composite™ to Treat Undernourished Young Children
|
N/A | |
Recruiting |
NCT02833740 -
Comparing Performance of Simplified Mid-Upper Arm Circumference Devices ("Click-MUACs") to Detect Acute Malnutrition
|
N/A | |
Recruiting |
NCT03408067 -
Evaluation of the Efficacy of Nutritional Risk Screening Tests, NRS 2002 and SGA, to Identifying Malnourished Patients
|
N/A | |
Completed |
NCT02938234 -
Tolerance and Compliance of a High Caloric, High Protein Oral Nutritional Supplement - Free Intake
|
N/A | |
Completed |
NCT02938247 -
Tolerance and Compliance of a High Caloric, High Protein Oral Nutritional Supplement - Scheduled Intake
|
N/A |